|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
Crypto.com's native token, Cronos (CRO), saw a significant increase in value yesterday (Monday).
Mar 25, 2025 at 07:11 pm
Crypto.com's native token, Cronos (CRO), saw a significant increase in value yesterday (Monday). The token's price surged by 27.76% within a 24-hour period.

Cronos (CRO), the native token of cryptocurrency platform Crypto.com, has seen a significant surge in value, increasing by 27.76% in the past 24 hours.
As of 08:05 ET on Tuesday, Cronos is trading at $0.1065, with a 24-hour trading volume of $326.47 million. The cryptocurrency's market capitalization has grown to $2.8 billion.
CRO Price Analysis: H1 Chart
The H1 chart of CROUSD shows a strong bullish momentum that has driven a significant upward price surge. The buyers managed to push the price to the 0.1200 level, where sellers reacted and formed a rejection pattern.
This rejection at the 0.1200 level has led to the formation of a bearish inside bar pattern, which is a low-volatility price action pattern that occurs when the current candle is fully enclosed by the previous candle.
Following the inside bar pattern, two consecutive bearish candles have decreased the price further, and the coin is currently trading around the 0.1065 level.
Buyers may want to wait for a bullish reversal pattern to re-enter long positions, while intraday traders may prefer to scalp and capture some pips as the market trends remain bearish.
Crypto.com to Provide Technology for ETFs
Earlier this month, Trump Media and Technology Group announced plans to develop exchange-traded funds (ETFs) in partnership with Crypto.com and Yorkville America.
The ETFs will feature a mix of digital and traditional assets, with one ETF including a basket of cryptocurrencies, such as Crypto.com’s CRO token.
Crypto.com will contribute its US trust company, Crypto.com Custody Trust Company, to handle the backend technology and custody services. The company will also provide the cryptocurrency for these ETFs.
Investors will be able to purchase the funds via Foris Capital US LLC, Crypto.com’s broker-dealer. The company’s holding subsidiary, DeFi Technologies, Inc., will offer the funds in Europe.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
- Datavecta Forges Global Community Ecosystem to Power International Growth Through Advanced SEO Strategy
- Sep 30, 2026 at 07:55 pm
- Datavecta is building a global community ecosystem to enhance international growth, leveraging advanced SEO strategies and technology-driven services for a connected intelligent trading future.
-
- Illinois Rolls Out Draft Rules for 0.2% Crypto Transaction Tax, Set for 2027
- Sep 30, 2026 at 12:05 pm
- Illinois unveils draft regulations for its upcoming 0.2% digital asset transaction tax, impacting exchanges, transfers, and custody services starting January 1, 2027. The tax applies to the gross value of transactions, not investment gains.
-
-
- Apeing Leads the Charge: Unveiling the Next 100x Crypto Watchlist and 6 Coins to Eye
- Sep 30, 2026 at 12:03 pm
- Amidst a dynamic crypto market, Apeing's presale momentum, coupled with established players like Solana and TRON, is redefining the 100x crypto narrative, offering both early-stage opportunities and proven network strength.
-
-
- OpenAI Unveils GPT-6.1 Sol and Ultrafast Tier, While AstraZeneca Invests Big in Summit Therapeutics
- Sep 30, 2026 at 08:05 am
- OpenAI rolls out GPT-6.1 Sol, offering near-Astra performance at a fraction of the cost, alongside a new 'Ultrafast' speed tier. Meanwhile, AstraZeneca makes a significant $2 billion investment in oncology firm Summit Therapeutics.
-
-
































